Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting

Presentation highlights first clinical study of ATX-295, a potentially best-in-class oral KIF18A inhibitor, in patients with advanced or metastatic solid tumors LEXINGTON, Mass., May 21, 2026 /PRNewswire/ -- Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel...